Inclusion Criteria:

- Patients with resectable pancreatic adenocarcinoma

- Age over 18 years old and younger than 70 year old

- Performance status (ECOG scale): 0-1

- Adequate organ functions

- Hb ≥9.0 g/dl

- ANC ≥1,500/mm3

- PLT ≥100,000/mm3

- Liver function: Total Bilirubin ≤3.0 mg/dl AST/ALT/ALP ≤3× upper limit of normal

- Creatinine ≤1.5 ULN

- Patients should sign a written informed consent before study entry.

Exclusion Criteria:

- Tumor type other than adenocarcinoma

- Unresectable for resection on preoperative evaluation

- Other primary malignancy (except in situ carcinoma of the cervix or adequately
treated basal cell carcinoma of the skin or prior malignancy treated more than 5
years ago without recurrence)

- Prior systemic therapy (for instance, cytotoxic chemotherapy or active/passive
immunotherapy)

- Prior radiotherapy

- Major surgery within 4 weeks prior to study treatment

- Serious illness or medical conditions, as follows;

- congestive heart failure (NYHA class III or IV)

- unstable angina or myocardial infarction within the past 6 months,

- significant arrhythmias requiring medication and conduction abnormality such as
over 2nd degree AV block

- uncontrolled hypertension

- hepatic cirrhosis( ≥ Child class B)

- interstitial pneumonia, pulmonary adenomatosis

- psychiatric disorder that may interfere with and/or protocol compliance

- unstable diabetes mellitus

- uncontrolled ascites or pleural effusion

- active infection

- Received any investigational drug or agent/procedure, i.e. participation in another
trial within 4 weeks before beginning treatment with study drug

- Pregnant or lactating woman

- Women of child bearing potential not using a contraceptive method

- Sexually active fertile men not using effective birth control during medication of
study drug and up to 6 months after completion of study drug if their partners are
women of child-bearing potential

- Any patients judged by the investigator to be unfit to participate in the study